Press release
Exosomes Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, "Exosomes Pipeline Insight 2025" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight's comprehensive report today! @ Exosomes Pipeline Outlook [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Exosomes Pipeline Report
* In February 2025, Aegle Therapeutics announced a trial is a prospective, open label, randomized, multi-center study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs to 10-50 cm2 wounds in RDEB subjects with wounds persisting for at least four weeks.
* DelveInsight's Exosomes pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Exosomes treatment.
* The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics , and others.
* Promsiing Exosomes therapies such as Anlotinib, AGLE 102, TISSEEL , and others.
Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Exosomes Emerging Drugs Profile
* CAP-1002: Capricor
Capricor's (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor's scientific founder, Dr. Eduardo Marban. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. CAP-1002 contains cardiosphere-derived cells, a type of heart cell progenitor, or precursor cell, that secretes tiny vesicles called exosomes. These exosomes then modulate the activity of the immune system and stimulate cellular regeneration. It is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. Currently, the drug is in Phase III stage of its development for the treatment of Duchenne Muscular Dystrophy.
* Progenza: Regeneus
Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. The MSCs are expanded through the company's proprietary and scalable manufacturing process. The company has demonstrated the capacity to produce millions of therapeutic doses of Progenza from a single donor. When Progenza cells are injected into the damaged joint or tissue, the MSCs have the potential to reduce pain and inflammation and slow the progression of disease. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Osteoarthritis.
* AGLE 102: Aegle Therapeutics
AGLE-102 contains COL7 protein as well as COL7A1 mRNA, which in preclinical models stimulates recessive DEB cells (cannot make any COL7) to produce COL7. AGLE-102 has the potential to induce functional regeneration and organization of complex tissue structures in DEB and EB patients that can potentially accelerate and enhance healing, reduce scarring, and improve overall cosmesis. In addition, AGLE-102 is non-immunogenic and carries the immunomodulating and anti-inflammatory properties of MSCs. Aegle's Phase I/II clinical trial involving AGLE-102 in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment. Currently, the drug is in Phase I/II stage of its development for the treatment of Dystrophic Epidermolysis Bullosa.
The Exosomes Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
* Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market
Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight's detailed report now! @ New Exosomes Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Exosomes Companies
Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Exosomes Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Exosomes Market Drivers and Barriers [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Exosomes Pipeline Report
* Coverage- Global
* Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics , and others.
* Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others.
* Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Exosomes : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Exosomes - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CAP-1002: Capricor Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Progenza: Regeneus
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* AGLE 102: Aegle Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Exosomes Key Companies
* Exosomes Key Products
* Exosomes - Unmet Needs
* Exosomes - Market Drivers and Barriers
* Exosomes - Future Perspectives and Conclusion
* Exosomes Analyst Views
* Exosomes Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exosomes-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exosomes Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3925065 • Views: …
More Releases from ABNewswire

Author's Tranquility Press Presents: "Confessions of a Corgi Doodler" - A Whimsi …
Nancy Kondos' Delightful New Book Celebrates the Art of Imperfect Doodles and the Irresistible Charm of Corgis
Author's Tranquility Press is thrilled to announce the release of Confessions of a Corgi Doodler [https://www.amazon.com/Confessions-Corgi-Doodler-Nancy-Kondos/dp/1966972717/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.nrKIgvSORUypy55MCVfP6A.Y5mWYYbHvQvFWtTL1ag6iD8erODCj3RPU4WsPh-Bvdo&qid=1758212447&sr=1-1], a charming and beautifully illustrated book by author and artist Nancy Kondos. This heartwarming collection invites readers into a world where pens dance freely, lines wobble with personality, and Corgis come to life in the most unexpectedly joyful…

Author's Tranquility Press Presents: "A Parent's Guide for Educational Success f …
From choosing the right school and managing seasonal illnesses to nurturing resilience during family changes, this guide offers practical, heartfelt wisdom for raising confident, well-rounded learners.
Author's Tranquility Press is proud to announce the release of A Parent's Guide for Educational Success for Their Children [https://www.amazon.com/Parents-Guide-Educational-Success-Children-ebook/dp/B09VDKQ61G/ref=monarch_sidesheet_image] by Joann Falciani-a deeply insightful, compassionate, and immensely practical resource for parents navigating the often-overwhelming journey of their child's education.
Packed with real-world advice, actionable strategies,…

VMFS USA Steps Up Smart Vending Capabilities with AI Vision, Fresh Coffee, and F …
MIAMI, FL - September 25, 2025 - VMFS USA, a U.S.-based vending machine manufacturer and supplier, has stepped up its vending technology offerings with a set of advanced upgrades across its product categories. The company is now offering AI-powered Grab-and-Go vending machines with integrated weight sensing and machine vision, a dual-mode coffee vending machine capable of serving both hot and iced beverages from freshly ground beans, and a redesigned hot…

Jaclyn Fortier and Carolina Counseling Wellness Associates Champion Storytelling …
GREENSBORO, NC - In an era where silence and isolation often go hand in hand with emotional struggle, Jaclyn Fortier is leading a movement that embraces storytelling as a powerful form of personal healing. Through her work at Carolina Counseling Wellness Associates, Fortier is creating intentional spaces for people to share, reflect, and grow, not just through therapy, but through the deep act of writing and speaking their truths.
Image: https://www.abnewswire.com/upload/2025/09/35bf6550290b990b09a068867e91efe5.jpg
"Self-discovery,…
More Releases for Exosomes
Exosomes Researh: the Southeast Asia Exosomes market size is projected to reach …
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Exosomes- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market…
Exosomes Development and Exosomes Manufacturing Market Key Players Analysis - 10 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment…
Exosomes Development and Exosomes Manufacturing Market Know the Scope and Trends
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment…
Exosomes Development and Exosomes Manufacturing Market expected to Witness Huge …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment…
Exosomes Development and Exosomes Manufacturing Market Top Companies Study - 01 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment…
exosomes development and exosomes manufacturing market Revenue Report with Forec …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment…